Bicycle Therapeutics (BCYC) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bicycle Therapeutics (BCYC) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 54.1% versus a loss of 65.2%. Over five years, DRUG leads with a -7.3% price change compared with -94.7% for BCYC. Bicycle Therapeutics is the larger company by market cap ($203.3 million vs $201.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | DRUG |
|---|---|---|
| Share price | $2.90 | $20.40 |
| Market cap | $203.27M | $201.23M |
| 1-day change | -4.92% | -1.45% |
| YTD return | -59.04% | -73.86% |
| 1-year return | -54.11% | -65.18% |
| 5-year return | -94.69% | -7.27% |
| EPS (TTM) | $-2.03 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.59M | — |
| Revenue growth (YoY) | +105.77% | — |
| Net income (latest FY) | $-218.96M | — |
| Operating margin | -340.38% | — |
| Net margin | -301.66% | — |
| 52-week high | $7.83 | $123.75 |
| 52-week low | $2.85 | $17.40 |
| Distance from 52-week high | -62.96% | -83.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +216.21% | +426.18% |
| Average volume | 444.72K | 173.24K |
| Shares outstanding | 50.66M | 9.86M |
| Employees | 288 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCYC has outperformed DRUG by 11.1 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
BCYC vs DRUG FAQ
Which is bigger, Bicycle Therapeutics or Bright Minds Biosciences?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $203.27M compared with $201.23M for Bright Minds Biosciences (DRUG).
Which stock has performed better over the past year, BCYC or DRUG?
BCYC returned -54.11% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.